Check4Cancer is shortlisted in two award categories in the 2022 Health Investor Awards

Check4Cancer is delighted to announce that we have been shortlisted in both the ‘Technology Provider of the Year’ and ‘Diagnostic Provider of the Year’ categories at the 2022 Health Investor Awards.

Check4Cancer was crowned winner in the category of ‘Diagnostics Provider of the Year’ at the 2018 Health Investor Awards and we had previously been finalists in this category for three years in a row. Check4Cancer was praised in our 2018 winning entry on our “high-quality patient-centred, medically led service with clear targets for an effective one-stop approach diagnostic pathway” and its “level of clinical audit underpinning the outcomes”.  Our 2022 nomination in this category is how we have managed to not just maintain but significantly grow our breast and skin diagnostic pathway activity throughout the pandemic, especially in 2021, while maintaining key performance standards.

Our shortlisted nomination in the ‘Technology Provider of the Year’ category is for our online risk assessment tool, called MyCancerRisk, and our Cancer Impact Calculator which helps corporates and insurers estimate their return on investment in cancer screening. Professor Gordon Wishart, founder, and CEO of Check4Cancer comments; “I am really proud of all our employees at Check4Cancer who helped design, develop and deploy our online cancer risk assessment tool within a two-year period. With the current disruption to UK cancer services, there has never been a more important time to support cancer screening in the corporate and insured sectors’’.

The prestigious Health Investor Awards which are now in their 15th year celebrate excellence and recognise innovation in the healthcare sector. The awards ceremony takes place on the 8th June at the Grosvenor House Hotel in London. Click here to find out more.